Treo Ventures’ Post

👏 InterVene, Inc. raised $13 million in a Series A financing round to support its Recana catheter system. New investor Treo Ventures and existing investor RiverVest Venture Partners co-led the round. 🚀CEO Jeff Elkins commented: “RiverVest and Treo Ventures have strong track records in emerging endovascular fields and InterVene is thrilled to have their support as Recana reaches its final phases of development. We are excited to work with these seasoned, accomplished teams on such a significant opportunity to help physicians and their patients with venous conditions.” 🔗 Read more: https://lnkd.in/dYAq3JZA #MedicalDevice #MedTech #MedicalEquipment #HealthTech #SeriesA #MedicalDevices #Medicine #TechNews #Funding #MedTechFunding #FundingRound #AngelInvestment #GSCapitalConnect

Congrats to Vivalyx, an innovative Organ Vitality Tech startup based in Aachen, on successfully closing an oversubscribed seed funding round, raising above EUR 5 million. Investors include leading European Life Science and Deeptech venture capital firms such as Brightlands Venture Partners, TechVision Fonds, Arve Capital, the American Deeptech VC Goose Capital, and notable private angel investors.   The funding enables Vivalyx to finance the clinical study required for regulatory approval. This crucial step paves the way for the launch of the innovative organ preservation solution, which has the potential to extend the lifespan of donor organs and enhance their vitality. Vivalyx technology aims to significantly increase the number of organs available for transplantation, thus saving and improving the lives of patients worldwide – at significantly lower costs, considerably reduced complexity, and streamlined processes.   Thumbs up also to the international Orrick team including Ilona Schütz, David Hamala, Sven Greulich, Benedikt Migdal and further colleagues.   Orrick, Herrington & Sutcliffe LLP #medtech #lifesciences #organdonation #venturecapital #founders #innovation #TeamOrrick

At least 50 biotechs announced private financing rounds of $100 million or more In the first half of the year, according to Endpoints News. Most of these companies were already in the clinic, meaning a data readout or big de-risking event is on the horizon. About 15 of the 50 companies were not yet in the clinic at the time of a financing announcement. Most venture dollars are being invested in oncology, obesity, autoimmune and neuroscience. Tim Opler, an investment banker at Stifel who tracks the industry wrote in his June 16 report, “Nonetheless, venture funding is going more and more into ‘megarounds,’ and it is not easy for emerging companies lacking superstar management to raise capital.” https://lnkd.in/eQTh7yD5 #venturecapital #biotech #insights

🥇 I am beyond moved to win the W.A. De Vigier Stiftung award 🥇 One of the most emotional feelings in my life 💖 . When I was called out for the last winning prize as one of the six startups, my legs went weak and then it hit me that all the hard work pays off. Simon Ittig with his speech was just right. As a founder you will sometimes question the sense of running your startup, but you just need to trust the process and keep working. As André Hoffmann said that evening: never stop innovating! And this is our promise because the fascination for innovation is what drives us every day! I am extremely grateful to the entire De Vigier Foundation for the belief and the trust in the execution of Treeless Pack’s mission to replace fossil-based materials with bio-based cellulose materials using microorganisms. 🙏 A heartfelt thank you to the whole W.A. De Vigier Stiftung: The management - Hanna Byland, Carmen Lamparter The board - André Hoffmann Theresa Visarius Carolyn J. Lutz Alain Nicod Felix Grisard Wolfgang Heutschi Guy Petignat Pirmin Bischof The De Vigier Family The Selection experts - Christian Brand and Michael Sauter A shout-out goes also to the FERS Stiftung Last but not least, I would emphasize the importance of the whole journey of the competition. We created an amazing group of like-minded entrepreneurs that share the same values and hopefully beyond the prizes and the reputation, the competition will result in long- lasting relationships among the alumni! 🤝 Julia A. Carpenter apheros Alessandro Morra Ascento Kevin Yim, PhD EVIIVE Rajiv Singhal Grensol Group Aris Maroonian Neology Hydrogen Dr. Evan Petkov Optiml Anand V. PEROVSKIA SOLAR AG Mamta Chabria, PhD Tandem Therapeutics Jonas Wüst Tethys Robotics And finally, I would like to thank my amazing co-founder Patrycja Kucharczyk who has been at Treeless from the very beginning. Last: We are 🚀 FUNDRAISING 🚀, so if you want to invest in the future of bio-based materials please get in touch! 🌿 👨🔬 #innovation #motivation #award #DeVigier #founders #fundraising #sustainability #cleantech #materials

Venture philanthropy as enabler for progress toward curing paralysis: way to go! Hopefully next investments can include therapies focusing on chronic spinal cord injury and on neuro-regeneration / biological repair of the spinal cord.

#Neurotech startup Neurovalens lands £2.1m and FDA clearance 💪 Securing a £2.1 million ($2.65 million) funding round and receiving FDA clearance for their Modius Stress headband, the Belfast-based team are pushing forward with their solution to combat anxiety. Their Modius headband administers gentle electrical pulses during 30-minute sessions, offering a promising avenue for managing generalised anxiety disorder (GAD). The new investments were raised from previous investors including MedTech Innovator, Invest Northern Ireland, Techstart Ventures, Angel Co Fund, Beltrae Partners, Clarendon Fund Management, British Business Bank, IQ Capital and Wharton Asset Management. Neurovalens believe their technology has broader potential beyond purely GAD. The company states that the “low-risk, non-invasive therapeutic intervention offered by Neurovalens technology will be truly transformative for a range of serious medical conditions.” FDA clearance for Modius Stress is a step in the right direction. #neurotech #funding #FDA

Dan Primack of Axios has some choice words for VCs in this post. If you are an investor, LP or a founder raising money from VCs - worth the read. I tend to agree with Dan here and have some thoughts... 1) Private Equity is an ecosystem that relies on flow not a one-way transfer of assets. VC is semi-broken right now because no one wants to sell off a portfolio below performance targets. Could mean game over for the GPs. Seems like public, private and venture are all trying to remain optimistic while waiting for a drop in interest rates and an uptick in IPOs or PE buyouts to start the liquidity flow again but Fed and inflation data keep frustrating this kicking off. 2) VC have one core job as far as LPs are concerned....Create a magic black box that is a cash multiplier. Not a black hole! When and how early investments become liquid need to change also. 3) We have an 80 year old VC fund model that requires wild, best-case scenario power-law returns to generate the performance numbers the asset class promises to investors. This handcuffs GPs to staying in deals for a very long time as the early exits or lower deal multiples can drag funds performance and then their job security, fee structure, etc as I alluded to above. This also drives companies to "go big or go home" and operate with inherently more risk than stability. 4) Dan talks about the need for liquidity and to get back to the money flow. This is easier said than done as a minority investor. Incrementally easier if you and your co-investors are able to steer the company at the board level but its still "not your company" and the "market is the market" re comps/multiples and demand. 5) So - what can we, as an industry, do about this? We have to evolve. We have to have some hard conversations around the table and not let staid endowment funds and Goldman Sachs dictate how our industry looks at the future...feel like this becomes a new post or a series so I'll leave it here for now. #venture #VC #startups #privatequity

We're excited to share that Remepy has successfully raised a $10M Seed round, bringing their total funding to $15M. We are thrilled to be part of this company's journey as their pre-seed investors and to participate in this round as well. A big welcome to the new funds joining, NFX that led the round joined by Vine Ventures, L.P., PsyMed Ventures, Supernode Ventures, and Firstime VC. A big shoutout to the existing investors TechAviv, 97212 Ventures, StageNext Fund, Samsung Next and all the angels on board. Another big welcome to Dr. Danny Bar Zohar, Merck’s Global Head of R&D and Chief Medical Officer, who has joined Remepy's board. His expertise will undoubtedly propel the company's mission forward. Dr. Bar Zohar is joining world-class personas who are already on Remepy's scientific, advisory and company's board such as Former PM Naftali Bennett, Prof. Michal Schwartz, Jessica J. Federer and Jonathan MacQuitty. Remepy is pioneering the "hybrid drugs" category. The company's hybrid drug combine traditional drugs with its “digital molecules.” Digital molecules are therapeutic interventions that trigger physiological effects (aka MOAs, Mechanisms of Action) through the brain. These physiological changes have been known to enhance the effectiveness of traditional drugs. Hats off to Michal Tsur, Or Shoval, Prof. Amir Amedi, Shahar Shelly M.D and the entire Remepy team for reaching finalizing this round and reaching this important milestone. Your dedication and innovative approach are reshaping the pharma and health industries and has incredible potential to improve patient outcomes. For more details on how Remepy is pioneering the hybrid drug category and to learn more about the science behind it, visit Remepy's website (link in the comments)

Investors for Global Digital Therapeutics (DTx) Startups  Through an extensive search and review of publicly available information, 172 startups were selected for detailed analysis regarding their fundraising status. Among these, 94 Digital Therapeutics (DTx) startups have collectively raised $6.859 billion from global investors. These startups include Raft Digital Therapeutics, Mindable Health GmbH, MicroHealth, Vigo Health, SleepUp, Vitadio s.r.o., Neurolief, OPTT Health, Vivira Health, XR Therapeutics, and many others. They are supported by a diverse range of investors, such as aMoon Fund, Expansion Capital, UV-Cap, 7wireVentures, Accelmed Partners, Adage Capital Management, and BCG Digital Ventures, among others. This substantial funding highlights the growing investor confidence and interest in DTx innovations. #dtx #digitaltherapeutics #startup #vc #funding #fundraising #investment

#fundingalert 💼Company: Outpace Bio 💰Funding: $144 Million ⚡Round: Oversubscribed Series B 👥Investors: RA Capital Management, with participation from new investors Qatar Investment Authority (QIA), Surveyor Capital (a Citadel company), Sheatree Capital, Black Opal Ventures, Alexandria Real Estate Equities, Inc., and other undisclosed investors. Outpace’s existing investors, ARTIS Ventures, Playground Global, Bristol Myers Squibb, Abstract Ventures, @Civilisation Ventures , Mubadala Capital, Breton Capital Ventures, WRF Capital, and Sahsen Ventures, LLC Ventures, Outpace Bio is using unrivalled AI-powered protein design to deliver on the promise of cell therapy for solid tumours by programming cells for improved function inside the patient. Jake Simson Read more - https://lnkd.in/gbnfUeBq To share your startup story write us on - contact@startuprise.io #fundraising #startups #healthcare #investment